Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.

ABSTRACT:

Objective

Patients prescribed second-generation antipsychotics (SGA) are at risk of antipsychotic induced weight gain (AIWG). The objective was to estimate weight changes after prescription of incretin-based weight loss medications by category of expected AIWG: high (olanzapine, clozapine), intermediate (risperidone, quetiapine, paliperidone) and low (e.g., asenapine, aripiprazole).

Methods

We conducted a retrospective cohort study using electronic health records (June 2021-December 2023) from Epic Cosmos for adults (≥18 years) without diabetes, prescribed SGA, and eligible for incretin-based weight loss medications. We studied changes in weight (kg) and the probability of at least 5% weight loss after 6 months of prescription of incretin-based medications by categories of A

SUBMITTER: Varghese JS 

PROVIDER: S-EPMC12634428 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature